{"id":"https://openalex.org/W950120787","doi":"https://doi.org/10.1016/j.jalz.2015.06.1893","title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients","display_name":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients","publication_year":2015,"publication_date":"2015-07-31","ids":{"openalex":"https://openalex.org/W950120787","doi":"https://doi.org/10.1016/j.jalz.2015.06.1893","mag":"950120787","pmid":"https://pubmed.ncbi.nlm.nih.gov/26238576"},"language":"en","primary_location":{"id":"doi:10.1016/j.jalz.2015.06.1893","doi":"https://doi.org/10.1016/j.jalz.2015.06.1893","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2015.06.1893","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2015.06.1893","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2015.06.1893","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080609944","display_name":"Eric Siemers","orcid":"https://orcid.org/0000-0001-7125-1550","observed_orcids":["https://orcid.org/0000-0001-7125-1550"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric R. Siemers","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105691065","display_name":"Karen L. Sundell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen L. Sundell","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110002052","display_name":"Christopher D. Carlson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Carlson","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110754652","display_name":"Michael G. Case","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Case","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109144493","display_name":"Gopalan Sethuraman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gopalan Sethuraman","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085051732","display_name":"Hong Liu\u2010Seifert","orcid":"https://orcid.org/0000-0002-9534-0483","observed_orcids":["https://orcid.org/0000-0002-9534-0483"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Liu\u2010Seifert","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109982907","display_name":"Sherie A. Dowsett","orcid":"https://orcid.org/0009-0000-6388-0250","observed_orcids":["https://orcid.org/0009-0000-6388-0250"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sherie A. Dowsett","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063370924","display_name":"Michael J. Pontecorvo","orcid":"https://orcid.org/0000-0002-8419-7589","observed_orcids":["https://orcid.org/0000-0002-8419-7589"]},"institutions":[{"id":"https://openalex.org/I4391768101","display_name":"Avid Radiopharmaceuticals (United States)","ror":"https://ror.org/00szax507","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4391768101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Pontecorvo","raw_affiliation_strings":["Avid Radiopharmaceuticals, Philadelphia PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avid Radiopharmaceuticals, Philadelphia PA, USA","institution_ids":["https://openalex.org/I4391768101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103710320","display_name":"Robert A. Dean","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Dean","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024765227","display_name":"Ronald Bradley Demattos","orcid":"https://orcid.org/0009-0008-7651-1807","observed_orcids":["https://orcid.org/0009-0008-7651-1807"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Demattos","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5080609944"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":{"value":4200,"currency":"USD","value_usd":4200},"fwci":22.2464,"has_fulltext":true,"cited_by_count":383,"citation_normalized_percentile":{"value":0.99881443,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"12","issue":"2","first_page":"110","last_page":"120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.02710000053048134,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/solanezumab","display_name":"solanezumab","score":1.0},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9330000281333923}],"concepts":[{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5932496190071106},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5490879416465759},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.545301079750061},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5432925820350647},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5336825251579285},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.5289685130119324},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.4946233928203583},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4839239716529846},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.47445544600486755},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3215848207473755},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.31566286087036133},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2857685089111328},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.12318256497383118},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08051052689552307},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000203","descriptor_name":"Activities of Daily Living","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003071","descriptor_name":"Cognition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009483","descriptor_name":"Neuropsychological Tests","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jalz.2015.06.1893","doi":"https://doi.org/10.1016/j.jalz.2015.06.1893","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2015.06.1893","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2015.06.1893","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},{"id":"pmid:26238576","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26238576","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & dementia : the journal of the Alzheimer's Association","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1016/j.jalz.2015.06.1893","doi":"https://doi.org/10.1016/j.jalz.2015.06.1893","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2015.06.1893","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2015.06.1893","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W950120787.pdf","grobid_xml":"https://content.openalex.org/works/W950120787.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1558115577","https://openalex.org/W1594253127","https://openalex.org/W1847168837","https://openalex.org/W1901655397","https://openalex.org/W1953027527","https://openalex.org/W1967549235","https://openalex.org/W1984388590","https://openalex.org/W1984496263","https://openalex.org/W1996776294","https://openalex.org/W2001436176","https://openalex.org/W2011183205","https://openalex.org/W2013078308","https://openalex.org/W2015484447","https://openalex.org/W2015514982","https://openalex.org/W2024719735","https://openalex.org/W2025152196","https://openalex.org/W2030067782","https://openalex.org/W2033252867","https://openalex.org/W2038003677","https://openalex.org/W2058614488","https://openalex.org/W2063808031","https://openalex.org/W2065706231","https://openalex.org/W2086572083","https://openalex.org/W2118753807","https://openalex.org/W2118935254","https://openalex.org/W2120361659","https://openalex.org/W2128047032","https://openalex.org/W2156220037","https://openalex.org/W2171682279"],"related_works":["https://openalex.org/W2470890654","https://openalex.org/W4389451106","https://openalex.org/W1991896775","https://openalex.org/W2104158772","https://openalex.org/W2015484447","https://openalex.org/W2331664530","https://openalex.org/W2041066239","https://openalex.org/W146373215","https://openalex.org/W2766608848","https://openalex.org/W4238912238"],"abstract_inverted_index":{"INTRODUCTION:":[0],"EXPEDITION":[1],"and":[2,25,52,74,100,135],"EXPEDITION2":[3],"were":[4,64],"identically":[5],"designed":[6],"placebo-controlled":[7],"phase":[8,180],"3":[9,181],"studies":[10,42],"assessing":[11],"effects":[12,170,187],"of":[13,49,105,125,132,140],"solanezumab,":[14],"an":[15],"antiamyloid":[16],"monoclonal":[17],"antibody":[18],"binding":[19],"soluble":[20],"amyloid-\u03b2":[21],"peptide,":[22],"on":[23,171],"cognitive":[24,73],"functional":[26,75,108,128],"decline":[27,76],"over":[28],"80":[29],"weeks":[30],"in":[31,55,174,188],"patients":[32],"with":[33,79],"mild-to-moderate":[34],"Alzheimer's":[35,91,101,121],"disease":[36],"(AD).":[37],"Primary":[38],"findings":[39,145,156,167],"for":[40,120,157],"both":[41],"have":[43],"been":[44],"published.":[45],"METHODS:":[46],"Secondary":[47],"analyses":[48],"efficacy,":[50],"biomarker,":[51],"safety":[53],"endpoints":[54],"the":[56,68,133,158],"pooled":[57],"(EXPEDTION":[58],"+":[59],"EXPEDITION2)":[60],"mild":[61,69,176,190],"AD":[62,70,160,177,191],"population":[63,161],"performed.":[65],"RESULTS:":[66],"In":[67],"population,":[71],"less":[72],"was":[77],"observed":[78],"solanezumab":[80,169],"(n":[81,86],"=":[82,87],"659)":[83],"versus":[84],"placebo":[85],"663),":[88],"measured":[89],"by":[90,149],"Disease":[92,102,122],"Assessment":[93],"Scale":[94],"Cognitive":[95],"subscale,":[96],"Mini-Mental":[97],"State":[98],"Examination,":[99],"Cooperative":[103,123],"Study-Activities":[104,124],"Daily":[106,126],"Living":[107,127],"scale":[109],"Instrumental":[110],"ADLs.":[111],"Baseline-to-endpoint":[112],"changes":[113],"did":[114],"not":[115],"differ":[116],"between":[117],"treatment":[118],"groups":[119],"scale,":[129],"basic":[130],"items":[131],"ADCS-ADL,":[134],"Clinical":[136],"Dementia":[137],"Rating":[138],"Sum":[139],"Boxes.":[141],"Plasma/cerebrospinal":[142],"fluid":[143],"biomarker":[144],"indicated":[146],"target":[147],"engagement":[148],"solanezumab.":[150],"Solanezumab":[151],"demonstrated":[152],"acceptable":[153],"safety.":[154],"Efficacy":[155],"moderate":[159],"are":[162],"also":[163],"provided.":[164],"DISCUSSION:":[165],"These":[166],"describe":[168],"efficacy/safety":[172],"measures":[173],"a":[175,189],"population.":[178,192],"Another":[179],"study,":[182],"EXPEDITION3,":[183],"will":[184],"investigate":[185],"solanezumab's":[186]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":19},{"year":2024,"cited_by_count":24},{"year":2023,"cited_by_count":24},{"year":2022,"cited_by_count":35},{"year":2021,"cited_by_count":33},{"year":2020,"cited_by_count":23},{"year":2019,"cited_by_count":37},{"year":2018,"cited_by_count":49},{"year":2017,"cited_by_count":57},{"year":2016,"cited_by_count":59},{"year":2015,"cited_by_count":13}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}